|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Little AG, Gay EG, Gaspar LE and Stewart
AK: National survey of non-small cell lung cancer in the United
States: Epidemiology, pathology and patterns of care. Lung Cancer.
57:253–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: Recent
advances and future directions. Oncologist. 13:(Suppl 1). 5–13.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Therasse P: Measuring the clinical
response. What does it mean? Eur J Cancer. 38:1817–1823. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelly K, Crowley J, Bunn PA Jr, et al:
Randomized phase III trial of paclitaxel plus carboplatin versus
vinorelbine plus cisplatin in the treatment of patients with
advanced non-small-cell lung cancer: A Southwest Oncology Group
trial. J Clin Oncol. 19:3210–3218. 2001.PubMed/NCBI
|
|
7
|
Yamamoto N, Nambu Y, Fujimoto T and
Koshiji M: A landmark point analysis with cytotoxic agents for
advanced NSCLC. J Thorac Oncol. 4:697–701. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paz-Ares L, de Marinis F, Dediu M, Thomas
M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et
al: Maintenance therapy with pemetrexed plus best supportive care
versus placebo plus best supportive care after induction therapy
with pemetrexed plus cisplatin for advanced non-squamous
non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3,
randomised controlled trial. Lancet Oncol. 13:247–255. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lara PN Jr, Redman MW, Kelly K, Edelman
MJ, Williamson SK, Crowley JJ and Gandara DR: Southwest Oncology
Group: Disease control rate at 8 weeks predicts clinical benefit in
advanced non-small-cell lung cancer: Results from Southwest
Oncology Group randomized trials. J Clin Oncol. 26:463–467. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He L, Teng Y, Jin B, Zhao M, Yu P, Hu X,
Zhang J, Li S, Gao Y and Liu Y: Initial partial response and stable
disease according to RECIST indicate similar survival for
chemotherapeutical patients with advanced non-small cell lung
cancer. BMC Cancer. 10:6812010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Travis WD, Colby TV and Sobin LH:
Histological classification of lung and pleural tumours. World
Health Organization - International Histological Classification of
Tumours: Histological Typing of Lung and Pleural Tumours (3rd).
Springer. (Geneva). 21–24. 1999.
|
|
12
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Coudert B, Ciuleanu T, Park K, Wu YL,
Giaccone G, Brugger W, Gopalakrishna P and Cappuzzo F: SATURN
Investigators: Survival benefit with erlotinib maintenance therapy
in patients with advanced non-small-cell lung cancer (NSCLC)
according to response to first-line chemotherapy. Ann Oncol.
23:388–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cesano A, Lane SR, Ross GA and Fields SZ:
Stabilization of disease as an indicator of clinical benefit
associated with chemotherapy in non-small cell lung cancer
patients. Int J Oncol. 17:587–590. 2000.PubMed/NCBI
|
|
16
|
Mandrekar SJ, An MW, Meyers J, Grothey A,
Bogaerts J and Sargent DJ: Evaluation of alternate categorical
tumor metrics and cut points for response categorization using the
RECIST 1.1 data warehouse. J Clin Oncol. 32:841–850. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ho C, Ramsden K, Zhai Y, Murray N, Sun S,
Melosky B and Laskin J: Less toxic chemotherapy improves uptake of
all lines of chemotherapy in advanced non-small-cell lung cancer: A
10-year retrospective population-based review. J Thorac Oncol.
9:1180–1186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rosell R, Carcereny E, Gervais R, et al:
Spanish Lung Cancer Group in collaboration with Groupe Français de
Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica:
Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): A multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang JC, Wu YL, Schuler M, M, Popat S,
Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al: Afatinib
versus cisplatin-based chemotherapy for EGFR mutation-positive lung
adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall
survival data from two randomised, phase 3 trials. Lancet Oncol.
16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lyman GH, Reiner M, Morrow PK and Crawford
J: The effect of filgrastim or pegfilgrastim on survival outcomes
of patients with cancer receiving myelosuppressive chemotherapy.
Ann Oncol. Apr 7–2015.pii: mdv174 (Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Uchino J, Hirano R, Tashiro N, Yoshida Y,
Ushijima S, Matsumoto T, Ohta K, Nakatomi K, Takayama K, Fujita M,
et al: Efficacy of aprepitant in patients with advanced or
recurrent lung cancer receiving moderately emetogenic chemotherapy.
Asian Pac J Cancer Prev. 13:4187–4190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fossella F, Pereira JR, von Pawel J,
Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna
A, Fidias P, et al: Randomized, multinational, phase III study of
docetaxel plus platinum combinations versus vinorelbine plus
cisplatin for advanced non-small-cell lung cancer: The TAX 326
study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fidias PM, Dakhil SR, Lyss AP, Loesch DM,
Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J,
Obasaju CK, et al: Phase III study of immediate compared with
delayed docetaxel after front-line therapy with gemcitabine plus
carboplatin in advanced non-small-cell lung cancer. J Clin Oncol.
27:591–598. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ciuleanu T, Brodowicz T, Zielinski C, Kim
JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et
al: Maintenance pemetrexed plus best supportive care versus placebo
plus best supportive care for non-small-cell lung cancer: A
randomised, double-blind, phase 3 study. Lancet. 374:1432–1440.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cappuzzo F, Ciuleanu T, Stelmakh L,
Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W,
Melezínek I, et al: Erlotinib as maintenance treatment in advanced
non-small-cell lung cancer: A multicentre, randomised,
placebo-controlled phase 3 study. Lancet Oncol. 11:521–529. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pérol M, Chouaid C, Pérol D, Barlési F,
Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G,
et al: Randomized, phase III study of gemcitabine or erlotinib
maintenance therapy versus observation, with predefined second-line
treatment, after cisplatin-gemcitabine induction chemotherapy in
advanced non-small-cell lung cancer. J Clin Oncol. 30:3516–3524.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Paz-Ares LG, de Marinis F, Dediu M, Thomas
M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et
al: PARAMOUNT: Final overall survival results of the phase III
study of maintenance pemetrexed versus placebo immediately after
induction treatment with pemetrexed plus cisplatin for advanced
nonsquamous non-small-cell lung cancer. J Clin Oncol. 31:2895–2902.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barlesi F, Scherpereel A, Gorbunova V,
Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M,
et al: Maintenance bevacizumab-pemetrexed after first-line
cisplatin-pemetrexed-bevacizumab for advanced nonsquamous
nonsmall-cell lung cancer: Updated survival analysis of the AVAPERL
(MO22089) randomized phase III trial. Ann Oncol. 25:1044–1052.
2014. View Article : Google Scholar : PubMed/NCBI
|
